Recently, epidermal growth factor receptor (EGFR) and tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib [6], are reported to be effective only in tumours with EGFR kinase domain mutations that are most common in ADC [7]. Here, EGFR is linked to neoplasm.